New scan could spot hidden cancers
NCT ID NCT06386653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested a new radioactive imaging agent called [123I]I-DARPIN-Ec1 in 10 people with lung or ovarian cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors on SPECT scans. Researchers compared the new scan results with standard imaging like CT or MRI to check if it could improve cancer detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[123I]I-DARPIN-Ec1 injection
What this could lead to
If successful, this could lead to a more precise imaging method to detect and monitor lung and ovarian cancers.
What could go wrong
This is a very early Phase 1 study with only 10 participants, so results may not apply broadly. The imaging agent's safety and effectiveness are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia